Alnylam announces innovative value-based agreement framework for Oxlumo (lumasiran) to accelerate access for patients with primary hyperoxaluria type 1 and deliver ultra-rare orphan disease pricing solutions to U.S. payers

Alnylam Pharmaceuticals

24 November 2020 - Expedited access to Oxlumo aims to support children and adults living with PH1 who face inevitable disease progression and irreversible kidney damage in the absence of new treatment options.

Alnylam Pharmaceuticals announced today a new framework for value-based agreements (VBAs) designed to help people with primary hyperoxaluria type 1 gain access to Oxlumo (lumasiran).

Alnylam is in active discussions with leading payers and has reached an agreement in principle with Express Scripts, Harvard Pilgrim, and Highmark to pursue VBAs for Oxlumo.

Read Alnylam Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Orphan drug , Market access